Report Description

United States soft tissue sarcoma market is poised to witness significant growth until 2025 owing to the rise in pool of patients suffering from different types of cancers including soft tissue sarcoma. The government’s focus on providing best healthcare facilities and increasing funding for the development of new drugs are some key factors supporting the growth of soft tissue sarcoma market. Moreover, rising awareness among people about chronic diseases such as soft tissue sarcoma is also acting as a major factor behind the market growth. Moreover, the rise in quality patient care and patent expiry of branded drugs are some other factors which are anticipated to drive the soft tissue sarcoma market growth in the United States during the next five years.

Soft tissue sarcoma is a rare type of cancer which can develop in soft tissues such as fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. There are around 50 different types of soft tissue sarcoma and most of them are difficult to diagnose as they may be mistaken for many other types of growths. The most common types occur in the arms and legs, and in the abdomen.

United States soft tissue sarcoma market can be segmented based on treatment, disease type, end user and region. Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Here, the chemotherapy treatment is the most common one and is expected to dominate the market during the forecast period. A combination of various anti-cancer drugs is used during this treatment and the success rate is comparatively high.

Major companies operating in United States soft tissue sarcoma market include GlaxoSmithKline LLC, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Co, Hoffmann-La Roche Inc, Johnson & Johnson Services, Inc., Teva Pharmaceuticals USA Inc, Celgene Corporation, BioHorizons, Zimmer Biomet Holdings Inc and MiMedx Group Inc, among others. With the use of latest technologies, manufacturers are focusing on launching new drugs which can be more effective for treatment of soft tissue sarcoma.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of United States soft tissue sarcoma market.
  • To forecast United States soft tissue sarcoma market based on treatment, disease type, end user, company and regional distribution.
  • To identify drivers and challenges for United States soft tissue sarcoma market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in United States soft tissue sarcoma market.
  • To identify and analyze the profile of leading players operating in the United States soft tissue sarcoma market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of soft tissue sarcoma treatment companies across United States. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated United States soft tissue sarcoma market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Soft tissue sarcoma drug manufacturers, companies/partners, hospital/oncology centers and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to soft tissue sarcoma
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as soft tissue sarcoma drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, United States soft tissue sarcoma market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United States Soft Tissue Sarcoma Market, By Treatment:
    • Targeted Therapy
    • Chemotherapy
    • Anti-Angiogenesis Drug
    • Radiation Therapy
  • United States Soft Tissue Sarcoma Market, By Disease Type:
    • Local Sarcoma
    • Regional Sarcoma
    • Metastatic Sarcoma
  • United States Soft Tissue Sarcoma Market, By End User:
    • Hospitals
    • Oncology Center
    • Long Term Care Center
  • United States Soft Tissue Sarcoma Market, By Region:
    • North-East
    • Mid-West
    • South
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States soft tissue sarcoma market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United States Soft Tissue Sarcoma Market

4.    Executive Summary

5.    Voice of Customer

6.    United States Soft Tissue Sarcoma Market Outlook

6.1.  Market Size & Forecast

6.1.1. By Value

6.2.  Market Share & Forecast

6.2.1.     By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy)

6.2.2.     By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma)

6.2.3.     By End User (Hospitals, Oncology Center, Long Term Care Center)

6.2.4.     By Company (2019)

6.2.5.     By Region

6.3.  Market Attractiveness Index

7.    United States Local Soft Tissue Sarcoma Market Outlook

7.1.  Market Size & Forecast

7.1.1. By Value

7.2.  Market Share & Forecast

7.2.1.     By Treatment

7.2.2.     By End User

7.3.  Competition Outlook

8.    United States Regional Soft Tissue Sarcoma Market Outlook

8.1.  Market Size & Forecast

8.1.1. By Value

8.2.  Market Share & Forecast

8.2.1.     By Treatment

8.2.2.     By End User

8.3.  Competition Outlook

9.    United States Metastatic Soft Tissue Sarcoma Market Outlook

9.1.  Market Size & Forecast

9.1.1. By Value

9.2.  Market Share & Forecast

9.2.1.     By Treatment

9.2.2.     By End User

9.3.  Competition Outlook

10.  Market Dynamics

10.1.              Drivers

10.2.              Challenges

11.  Market Trends & Development

12.  Policy & Regulatory Landscape

13.  United States Economic Profile

14.  Competitive Landscape

14.1.              Competition Outlook (Top Companies)

14.1.1.  GlaxoSmithKline LLC

14.1.2.  Eli Lilly and Company

14.1.3.  Pfizer, Inc.

14.1.4.  Bristol-Myers Squibb Co

14.1.5.  Hoffmann-La Roche Inc

14.1.6.  Johnson & Johnson Services, Inc.

14.1.7.  Teva Pharmaceuticals USA Inc

14.1.8.  Celgene Corporation

14.1.9.  BioHorizons

14.1.10.                Zimmer Biomet Holdings Inc

14.1.11.                MiMedx Group Inc

15.  Strategic Recommendations

16.  About Us & Disclaimer

 (Note: The companies list can be customized based on the client requirements.)

Figures and Tables

Frequently asked questions






Sakshi Bajaal

Business Consultant
Press Release

Unite States Soft Tissue Sarcoma Market Expected to Witness Rapid Growth until 2025

Jun, 2020

Government's focus on R&D activities in healthcare and increasing approvals for manufacture of generic drugs to drive United States soft tissue sarcoma market